CD274 and neoplasm: Preclinical studies demonstrate that systemic effects of RT in priming a systemic anti-tumor T cell response are achieved more reliably when RT is combined with anti-CTLA-4 and/or anti-PD-1/PD-L1 checkpoint blockade (42, 43).